Pemetrexed
Small molecule targets DHFR, GART, TYMS via inhibition
Regulatory milestones approvals, filings & regulatory actions · 13 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Label expansion | US (FDA) | AXTLE | — | 2025-10-03 | fda.gov ↗ |
| Label expansion | US (FDA) | PEMFEXY | — | 2022-12-14 | fda.gov ↗ |
| Label expansion | US (FDA) | PEMETREXED | — | 2022-11-22 | fda.gov ↗ |
| Label expansions (8) | US (FDA) | ALIMTA | — | 2008-09-26 – 2022-08-31 | fda.gov ↗ |
| Approved | EU (EMA) | Alimta | — | 2004-09-20 | europa.eu ↗ |
| Approved | US (FDA) | ALIMTA | — | 2004-02-04 | fda.gov ↗ |
Trials 687 · started per year
Also used as a comparator or background therapy in 627 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 191 trials | ||||||
| Phase 1 | NCT07699757 Background | Jul 2026 → Apr 2029 expected | non-small cell lung carcinoma, pancreatic ductal adenocarcinoma | Haisco Pharmaceutical Group Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT07608731 Background | Jun 2026 → Apr 2029 expected | diffuse large B-cell lymphoma of the central nervous system, large B-cell lymphoma | Allison Winter | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT07381829 Background | Oct 2025 → Dec 2026 expected | — | HC Biopharma Inc. | Recruiting | No outcome recorded |
| Phase 1 | NCT07004244 Background | Jun 2025 → Dec 2027 expected | cancer | Sichuan University | Recruiting | No outcome recorded |
| Phase 1 | NCT06969612 Background | May 2025 → May 2027 expected | non-small cell lung carcinoma | Peking University Cancer Hospital & Institute | Recruiting | No outcome recorded |
| Phase 1 | NCT06800339 Background | Apr 2025 → Mar 2028 expected | non-small cell lung carcinoma | University of Maryland, Baltimore | Recruiting | No outcome recorded |
| Phase 1 | NCT06883630 Background | Mar 2025 → Aug 2026 overdue | non-small cell lung carcinoma | RemeGen Co., Ltd. | Active not recruiting | No outcome recorded |
| Phase 1 | NCT06839105 Background | Feb 2025 → Apr 2028 expected | colorectal cancer, non-small cell lung carcinoma, renal cell adenocarcinoma | Shanghai Junshi Bioscience Co., Ltd. | Recruiting | No outcome recorded |
| Phase 1 | NCT05979818 Background | Nov 2024 → Aug 2025 overdue | non-small cell lung carcinoma | Second Xiangya Hospital of Central South University | Recruiting | No outcome recorded |
| Phase 1 | NCT06607185 Background | Oct 2024 → Jan 2030 expected | colorectal cancer, metastatic neoplasm, non-small cell lung carcinoma, pancreatic ductal adenocarcinoma | Eli Lilly and Company | Active not recruiting | No outcome recorded |
| Phase 1 | NCT06384352 Comparator | May 2024 → Jun 2031 expected | cancer | MediLink Therapeutics (Suzhou) Co., Ltd. | Recruiting | No outcome recorded |
| Phase 1 | NCT06253871 Background | Mar 2024 → Dec 2027 expected | HER2 positive breast carcinoma, gastroesophageal cancer, metastatic malignant neoplasm in the brain, non-small cell lung carcinoma +1 | Iambic Therapeutics, Inc | Recruiting | No outcome recorded |
| Phase 1 | NCT06091943 Background | Nov 2023 → Jul 2025 overdue | non-small cell lung carcinoma | BeiGene | Active not recruiting | No outcome recorded |
| Phase 1 | NCT03760575 Background | Jan 2023 → Feb 2027 expected | malignant pleural mesothelioma | Abramson Cancer Center at Penn Medicine | Recruiting | No outcome recorded |
| Phase 1 | NCT05254184 Background | Nov 2022 → Apr 2027 expected | non-small cell lung carcinoma | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Recruiting | No outcome recorded |
| Phase 1 | NCT06116240 Background | Sep 2022 → Dec 2023 | cancer | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Unknown | No outcome recorded |
| Phase 1 | NCT05382559 Background | Jun 2022 → Dec 2028 expected | cancer | Astellas Pharma Inc | Recruiting | No outcome recorded |
| Phase 1 | NCT05950815 Background | May 2022 → Sep 2023 | — | BioNTech SE | Unknown | No outcome recorded |
| Phase 1 | NCT05298592 Background | Mar 2022 → Aug 2024 | cancer of unknown primary site | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 1 | NCT05241873 Background | Mar 2022 → Jul 2024 | adenocarcinoma, bronchogenic carcinoma, metastatic malignant neoplasm in the brain, non-small cell lung carcinoma | Blueprint Medicines Corporation | Terminated | No outcome recorded |
| Phase 1 | NCT05153408 Background | Jan → Dec 2022 | adenocarcinoma, bronchogenic carcinoma, non-small cell lung carcinoma | Blueprint Medicines Corporation | Terminated | No outcome recorded |
| Phase 1 | NCT05067283 Background | Dec 2021 → Feb 2030 expected | cancer | Merck Sharp & Dohme LLC | Recruiting | No outcome recorded |
| Phase 1 | NCT05136846 Background | Dec 2021 → Dec 2026 expected | non-small cell lung carcinoma | Ohio State University Comprehensive Cancer Center | Recruiting | No outcome recorded |
| Phase 1 | NCT05117476 Background | Oct 2021 → Mar 2026 overdue | non-small cell lung carcinoma | Cullinan Therapeutics Inc. | Active not recruiting | No outcome recorded |
| Phase 1 | NCT05017012 Background | Sep 2021 → May 2026 | — | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 1 | NCT04861948 Background | May 2021 → Jul 2022 | lung adenocarcinoma, osteosarcoma | Innovent Biologics (Suzhou) Co. Ltd. | Terminated | No outcome recorded |
| Phase 1 | NCT04837716 Background | Mar 2021 → Sep 2027 expected | non-small cell lung carcinoma | M.D. Anderson Cancer Center | Active not recruiting | No outcome recorded |
| Phase 1 | NCT04686305 Background | Mar 2021 → Jun 2027 expected | non-small cell lung carcinoma | AstraZeneca | Recruiting | No outcome recorded |
| Phase 1 | NCT04649385 Background | Mar 2021 → Oct 2025 | neoplasm | BeiGene | Completed | No outcome recorded |
| Phase 1 | NCT04328844 Background | Feb 2020 → Dec 2023 overdue | myelofibrosis, non-Hodgkin lymphoma, non-small cell lung carcinoma, uveal melanoma | iOnctura | Active not recruiting | No outcome recorded |
| Phase 1 | NCT03023319 Background | Dec 2019 → May 2022 | cervical cancer, mesothelioma, non-small cell lung carcinoma, ovarian cancer +4 | Nagla Abdel Karim | Completed | No outcome recorded |
| Phase 1 | NCT04153565 Background | Dec 2019 → Sep 2022 | mesothelioma | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 1 | NCT04022876 Background | Sep 2019 → Jul 2022 | non-small cell lung carcinoma, small cell lung carcinoma | Aileron Therapeutics, Inc. | Terminated | No outcome recorded |
| Phase 1 | NCT04047862 Background | Aug 2019 → Aug 2024 | — | BeiGene | Completed | No outcome recorded |
| Phase 1 | NCT03920839 Background | Jul → Nov 2019 | malignant pleural mesothelioma, non-small cell lung carcinoma | Incyte Corporation | Withdrawn | No outcome recorded |
| Phase 1 | NCT03918278 Background | Jun 2019 → Jun 2025 | neoplasm | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 1 | NCT03846310 Background | Apr 2019 → Nov 2024 | non-small cell lung carcinoma | Arcus Biosciences, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT04287894 Background | Dec 2018 → Nov 2024 | non-small cell lung carcinoma | The Netherlands Cancer Institute | Terminated | No outcome recorded |
| Phase 1 | NCT03819465 Background | Dec 2018 → May 2023 overdue | non-small cell lung carcinoma | AstraZeneca | Active not recruiting | No outcome recorded |
| Phase 1 | NCT03715933 Background | Oct 2018 → Dec 2028 expected | Ewing sarcoma, colorectal adenocarcinoma | Inhibrx Biosciences, Inc | Recruiting | No outcome recorded |
| Phase 1 | NCT03564691 Background | Jul 2018 → Sep 2025 | neoplasm | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 1 | NCT03498222 Background | Jun 2018 → Jan 2020 | non-small cell lung carcinoma | Queen Mary University of London | Withdrawn | No outcome recorded |
| Phase 1 | NCT03530397 Background | Apr 2018 → Jul 2025 overdue | — | MedImmune LLC | Active not recruiting | No outcome recorded |
| Phase 1 | NCT03396445 Background | Feb 2018 → Sep 2024 | non-small cell lung carcinoma, triple-negative breast carcinoma | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 1 | NCT03366064 Background | Nov 2017 → Sep 2018 | non-small cell lung carcinoma | Asan Medical Center | Completed | No outcome recorded |
| Phase 1 | NCT03177291 Comparator | Sep 2017 → May 2021 | non-small cell lung carcinoma, squamous cell lung carcinoma | H. Lee Moffitt Cancer Center and Research Institute | Completed | No outcome recorded |
| Phase 1 | NCT02964689 Background | Apr 2017 → Jul 2021 | non-small cell lung carcinoma | Swiss Cancer Institute | Completed | No outcome recorded |
| Phase 1 | NCT02185690 Background | Mar 2017 → Jul 2019 | lung cancer | University Health Network, Toronto | Completed | No outcome recorded |
| Phase 1 | NCT02944396 Background | Dec 2016 → Oct 2019 | non-small cell lung carcinoma | AbbVie | Completed | No outcome recorded |
| Phase 1 | NCT02964013 Background | Dec 2016 → Jul 2024 | neoplasm | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 1 | NCT02817633 Background | Jul 2016 → Mar 2027 expected | neoplasm | Tesaro, Inc. | Active not recruiting | No outcome recorded |
| Phase 1 | NCT02723955 Background | Jun 2016 → Jul 2023 | neoplasm | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT02609776 Background | May 2016 → Dec 2026 expected | non-small cell lung carcinoma | Janssen Research & Development, LLC | Active not recruiting | No outcome recorded |
| Phase 1 | NCT02794571 Background | May 2016 → Nov 2024 | metastatic neoplasm | Genentech, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT02707666 Background | Feb 2016 → Apr 2023 | pleural mesothelioma | University of Chicago | Terminated | No outcome recorded |
| Phase 1 | NCT02535325 Background | Sep 2015 → Feb 2020 | lung adenocarcinoma, lung large cell carcinoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 1 | NCT02419495 Background | Jun 2015 → Sep 2024 | cutaneous melanoma, fallopian tube carcinoma, metastatic malignant neoplasm, metastatic melanoma +5 | M.D. Anderson Cancer Center | Terminated | No outcome recorded |
| Phase 1 | NCT01958372 Background | Aug 2014 → Oct 2017 | adenosquamous lung carcinoma, lung adenocarcinoma, lung large cell carcinoma | Barbara Ann Karmanos Cancer Institute | Completed | No outcome recorded |
| Phase 1 | NCT02083679 Background | Jul 2014 → Aug 2015 | non-small cell lung carcinoma | EMD Serono | Terminated | No outcome recorded |
| Phase 1 | NCT02124148 Background | Jun 2014 → Feb 2020 | breast cancer, colorectal neoplasm, metastatic neoplasm | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT02120807 Background | Apr 2014 → Jan 2023 | lung adenocarcinoma | Memorial Sloan Kettering Cancer Center | Completed | No outcome recorded |
| Phase 1 | NCT01868022 Background | Oct 2013 → Oct 2017 | neoplasm | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT01918761 Background | Jul 2013 → Sep 2016 | non-small cell lung carcinoma | Central European Cooperative Oncology Group | Terminated | No outcome recorded |
| Phase 1 | NCT01899989 Background | Jul 2013 → Oct 2024 | non-small cell lung carcinoma | Memorial Sloan Kettering Cancer Center | Completed | No outcome recorded |
| Phase 1 | NCT01783197 Background | Jun 2013 → Apr 2017 | non-small cell lung carcinoma | Canadian Cancer Trials Group | Completed | No outcome recorded |
| Phase 1 | NCT01836341 Background | Apr 2013 → Apr 2015 | non-small cell lung carcinoma | Memorial Sloan Kettering Cancer Center | Withdrawn | No outcome recorded |
| Phase 1 | NCT01803282 Background | Mar 2013 → Apr 2019 | breast cancer, colorectal cancer, gastroesophageal cancer, non-small cell lung carcinoma +1 | Gilead Sciences | Completed | No outcome recorded |
| Phase 1 | NCT01714037 Background | Aug 2012 → Nov 2014 | non-small cell lung carcinoma | Debiopharm International SA | Terminated | No outcome recorded |
| Phase 1 | NCT01655225 Background | Jul 2012 → Apr 2019 | breast cancer, cancer of unknown primary site, malignant mesothelioma, metastatic malignant neoplasm +2 | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT01447225 Background | Oct 2011 → Nov 2013 | cancer | Merrimack Pharmaceuticals | Completed | No outcome recorded |
| Phase 1 | NCT01301716 Background | Sep 2011 → Aug 2014 | — | Genentech, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT01358968 Background | Jun 2011 → Apr 2012 | cancer | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT01373463 Background | May 2011 → Jun 2012 | non-small cell lung carcinoma | Medical University of South Carolina | Terminated | No outcome recorded |
| Phase 1 | NCT01336842 Background | Apr 2011 → Jan 2017 | non-small cell lung carcinoma | University of California, Davis | Completed | No outcome recorded |
| Phase 1 | NCT01296568 Background | Feb → Dec 2011 | — | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT01169675 Background | Jul 2010 → Nov 2012 | neoplasm | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT01063478 Background | Feb 2010 → Jun 2011 | non-small cell lung carcinoma | University of Chicago | Terminated | No outcome recorded |
| Phase 1 | NCT00979576 Background | Oct 2009 → Feb 2015 | non-small cell lung carcinoma | Boehringer Ingelheim | Terminated | No outcome recorded |
| Phase 1 | NCT00974584 Background | Oct 2009 → Mar 2015 | non-small cell lung carcinoma | Genentech, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT00692159 Background | Jun 2008 → Jun 2010 | neoplasm | Tracon Pharmaceuticals Inc. | Completed | No outcome recorded |
| Phase 1 | NCT00703638 Background | May 2008 → Sep 2010 | breast cancer, colorectal cancer, head and neck cancer, lung cancer +4 | Masonic Cancer Center, University of Minnesota | Completed | No outcome recorded |
| Phase 1 | NCT01445392 Background | Nov 2007 → Jan 2014 | mesothelioma | National Cancer Institute (NCI) | Terminated | No outcome recorded |
| Phase 1 | NCT01287520 Background | Nov 2007 → Apr 2011 | cancer of unknown primary site | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT00560573 Background | Nov 2007 → Jun 2008 | non-small cell lung carcinoma | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT00573690 Background | Sep 2007 → Jun 2009 | cancer of unknown primary site | UNC Lineberger Comprehensive Cancer Center | Completed | No outcome recorded |
| Phase 1 | NCT00415636 Background | Jan 2007 → Mar 2010 | cancer | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT00528619 Background | Nov 2006 → Apr 2010 | neoplasm | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT02211833 Background | Oct 2006 → Feb 2009 | non-small cell lung carcinoma | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT00179699 Background | Sep 2005 → Nov 2006 | non-small cell lung carcinoma | Celgene Corporation | Terminated | No outcome recorded |
| Phase 1 | NCT00106626 Background | Aug 2005 → Dec 2007 | — | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 1 | NCT00502567 Background | Jan 2005 → Nov 2007 | — | AstraZeneca | Completed | No outcome recorded |
| Phase 1/270 trials | ||||||
| Phase 1/2 | NCT06694454 Background | Jul 2026 → Dec 2031 expected | non-small cell lung carcinoma | National Cancer Institute (NCI) | Recruiting | No outcome recorded |
| Phase 1/2 | NCT07551778 Background | May 2026 → Apr 2028 expected | colorectal cancer, non-small cell lung carcinoma | BOE Technology Group Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT06996782 Background | Nov 2025 → Feb 2029 expected | non-small cell lung carcinoma | AstraZeneca | Recruiting | No outcome recorded |
| Phase 1/2 | NCT07111520 Comparator | Sep 2025 → Jan 2029 expected | non-small cell lung carcinoma | BioNTech SE | Recruiting | No outcome recorded |
| Phase 1/2 | NCT07157956 Background | Sep 2025 → Aug 2028 expected | neoplasm | Convalife (Shanghai) Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT07131345 Background | Sep 2025 → Oct 2026 expected | malignant mesothelioma | National Cancer Center, China | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT07063329 Background | Aug 2025 → Mar 2028 expected | non-small cell lung carcinoma | Avistone Pharmaceutical (Ningbo) Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT07020221 Background | Jun 2025 → Dec 2028 expected | colorectal cancer, non-small cell lung carcinoma, pancreatic ductal adenocarcinoma | Verastem, Inc. | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06772623 Background | Mar 2025 → Nov 2027 expected | non-small cell lung carcinoma | AbbVie | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06741644 Background | Feb 2025 → Jan 2027 expected | cancer | CStone Pharmaceuticals | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06624059 Background | Nov 2024 → Aug 2026 overdue | non-small cell lung carcinoma | Hoffmann-La Roche | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT06385678 Background | Jul 2024 → Dec 2025 overdue | — | Jiangsu HengRui Medicine Co., Ltd. | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT06474455 Background | Jul 2024 → Jun 2029 expected | cancer | Shanghai Hengrui Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06195189 Background | Feb 2024 → Dec 2027 expected | non-small cell lung carcinoma | Sichuan University | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06758557 Background | Jan 2024 → Oct 2025 overdue | endometrial cancer, non-small cell lung carcinoma | Huabo Biopharm Co., Ltd. | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06162221 Background | Jan 2024 → Jun 2027 expected | non-small cell lung carcinoma | Revolution Medicines, Inc. | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06173505 Background | Dec 2023 → Dec 2025 | non-small cell lung carcinoma | Xencor, Inc. | Terminated | No outcome recorded |
| Phase 1/2 | NCT05978401 Background | Aug 2023 → Apr 2025 | non-small cell lung carcinoma | Guangzhou Gloria Biosciences Co., Ltd. | Unknown | No outcome recorded |
| Phase 1/2 | NCT05789082 Background | Jun 2023 → Jan 2032 expected | non-small cell lung carcinoma | Hoffmann-La Roche | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06136910 Background | May 2023 → May 2024 | non-small cell lung carcinoma | Fujian Cancer Hospital | Unknown | No outcome recorded |
| Phase 1/2 | NCT05469178 Background | Mar 2023 → Apr 2025 | non-small cell lung carcinoma | BerGenBio ASA | Terminated | No outcome recorded |
| Phase 1/2 | NCT05765084 Background | Feb 2023 → Oct 2027 expected | malignant pleural mesothelioma | University Hospital, Antwerp | Recruiting | No outcome recorded |
| Phase 1/2 | NCT05443126 Background | Sep 2022 → Mar 2027 expected | non-small cell lung carcinoma | Ellipses Pharma | Recruiting | No outcome recorded |
| Phase 1/2 | NCT05416775 Background | Aug 2022 → Jun 2026 | non-small cell lung carcinoma | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Unknown | No outcome recorded |
| Phase 1/2 | NCT05431270 Background | Aug 2022 → Dec 2027 expected | non-small cell lung carcinoma, pancreatic ductal adenocarcinoma | Phanes Therapeutics | Recruiting | No outcome recorded |
| Phase 1/2 | NCT05407675 Background | Aug 2022 → Aug 2024 | cancer | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 1/2 | NCT05098132 Background | Jan 2022 → Jan 2029 expected | non-small cell lung carcinoma | Synthekine | Recruiting | No outcome recorded |
| Phase 1/2 | NCT04430933 Background | Dec 2021 → Jun 2022 | non-small cell lung carcinoma | NextCure, Inc. | Withdrawn | No outcome recorded |
| Phase 1/2 | NCT05083481 Background | Oct 2021 → May 2026 | — | Astellas Pharma Global Development, Inc. | Terminated | No outcome recorded |
| Phase 1/2 | NCT04486833 Comparator | Sep 2021 → Mar 2028 expected | non-small cell lung carcinoma | Genprex, Inc. | Recruiting | No outcome recorded |
| Phase 1/2 | NCT04717375 Background | Apr 2021 → Jul 2025 | cancer | Sanofi | Terminated | No outcome recorded |
| Phase 1/2 | NCT04831658 Background | Mar 2021 → Sep 2023 | primary central nervous system lymphoma | Mingzhi Zhang | Unknown | No outcome recorded |
| Phase 1/2 | NCT04665206 Background | Mar 2021 → Nov 2029 expected | mesothelioma, non-small cell lung carcinoma | Vivace Therapeutics, Inc | Recruiting | No outcome recorded |
| Phase 1/2 | NCT04647344 Background | Nov 2020 → Dec 2023 | non-small cell lung carcinoma | Akeso | Completed | No outcome recorded |
| Phase 1/2 | NCT04958993 Background | Nov 2020 → Nov 2021 | non-small cell lung carcinoma | Shandong Cancer Hospital and Institute | Terminated | No outcome recorded |
| Phase 1/2 | NCT04198766 Background | Dec 2019 → Oct 2026 expected | gastric cancer, head and neck cancer, melanoma, non-small cell lung carcinoma +2 | Inhibrx Biosciences, Inc | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT04182698 Background | Nov 2019 → May 2021 | non-small cell lung carcinoma | Second Affiliated Hospital of Xi'an Jiaotong University | Unknown | No outcome recorded |
| Phase 1/2 | NCT04083599 Background | Sep 2019 → Dec 2025 overdue | colorectal carcinoma, head and neck squamous cell carcinoma, melanoma, non-small cell lung carcinoma +1 | Genmab | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT03970746 Background | Sep 2019 → Jul 2024 overdue | non-small cell lung carcinoma | PDC*line Pharma SAS | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT03559049 Background | Dec 2018 → May 2025 | non-small cell lung carcinoma | University of Michigan Rogel Cancer Center | Terminated | No outcome recorded |
| Phase 1/2 | NCT03706287 Background | Dec 2018 → Mar 2021 | lung cancer | Sichuan Cancer Hospital and Research Institute | Unknown | No outcome recorded |
| Phase 1/2 | NCT03663166 Background | Nov 2018 → Oct 2021 | non-small cell lung carcinoma | H. Lee Moffitt Cancer Center and Research Institute | Terminated | No outcome recorded |
| Phase 1/2 | NCT03636685 Background | Aug 2018 → Aug 2019 | adenocarcinoma, non-small cell lung carcinoma, squamous cell carcinoma | Chinese Academy of Medical Sciences | Unknown | No outcome recorded |
| Phase 1/2 | NCT03317496 Background | Dec 2017 → Jun 2021 | non-small cell lung carcinoma, urothelial carcinoma | Pfizer | Terminated | No outcome recorded |
| Phase 1/2 | NCT03319537 Background | Oct 2017 → Jun 2023 | mesothelioma | Memorial Sloan Kettering Cancer Center | Terminated | No outcome recorded |
| Phase 1/2 | NCT02649829 Background | Oct 2017 → Mar 2025 | malignant pleural mesothelioma | University Hospital, Antwerp | Completed | No outcome recorded |
| Phase 1/2 | NCT03267316 Background | Sep 2017 → Mar 2024 | colorectal cancer, non-small cell lung carcinoma, pancreatic ductal adenocarcinoma, triple-negative breast carcinoma | Cantargia AB | Completed | No outcome recorded |
| Phase 1/2 | NCT03138889 Background | Jun 2017 → Jul 2022 | non-small cell lung carcinoma | Nektar Therapeutics | Terminated | No outcome recorded |
| Phase 1/2 | NCT02983045 Background | Dec 2016 → Apr 2022 | gastric cancer, hormone receptor-positive breast cancer, melanoma, non-small cell lung carcinoma +3 | Nektar Therapeutics | Completed | No outcome recorded |
| Phase 1/2 | NCT02535312 Background | Mar 2016 → Dec 2022 overdue | malignant peritoneal mesothelioma, malignant pleural mesothelioma | National Cancer Institute (NCI) | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT02439450 Background | Apr 2015 → May 2021 | non-small cell lung carcinoma | Heat Biologics | Completed | No outcome recorded |
| Phase 1/2 | NCT02347917 Background | Feb 2015 → May 2018 | malignant pleural mesothelioma, non-small cell lung carcinoma | Sumitomo Pharma Co., Ltd. | Completed | No outcome recorded |
| Phase 1/2 | NCT02327078 Background | Nov 2014 → Jun 2020 | B-cell neoplasm, colorectal cancer, glioblastoma, head and neck cancer +3 | Incyte Corporation | Completed | No outcome recorded |
| Phase 1/2 | NCT02049060 Background | Jan 2013 → May 2016 | malignant pleural mesothelioma, non-small cell lung carcinoma | Armando Santoro, MD | Completed | No outcome recorded |
| Phase 1/2 | NCT01666977 Background | Aug 2012 → Nov 2015 | non-small cell lung carcinoma | Amgen | Completed | No outcome recorded |
| Phase 1/2 | NCT01139775 Background | Feb 2011 → May 2013 | non-small cell lung carcinoma | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1/2 | NCT01178411 Background | Aug 2010 → Jan 2019 | cancer | ArQule, Inc. | Completed | No outcome recorded |
| Phase 1/2 | NCT01126736 Comparator | Jun 2010 → Dec 2012 | non-small cell lung carcinoma | Eisai Inc. | Completed | No outcome recorded |
| Phase 1/2 | NCT01064648 Background | Mar 2010 → Jun 2018 overdue | malignant epithelioid mesothelioma, malignant pleural mesothelioma, sarcomatoid mesothelioma | National Cancer Institute (NCI) | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT01211275 Background | May 2009 → Nov 2012 | malignant pleural mesothelioma | The Netherlands Cancer Institute | Completed | No outcome recorded |
| Phase 1/2 | NCT00768755 Comparator | Jan 2009 → Mar 2011 | non-small cell lung carcinoma | Pfizer | Completed | No outcome recorded |
| Phase 1/2 | NCT00794417 Background | Nov 2008 → Jun 2011 | non-small cell lung carcinoma | Regeneron Pharmaceuticals | Terminated | No outcome recorded |
| Phase 1/2 | NCT00700336 Background | May 2008 → Jul 2012 | malignant pleural mesothelioma | CanBas Co. Ltd. | Completed | No outcome recorded |
| Phase 1/2 | NCT00668499 Background | Apr 2008 → Apr 2011 | mesothelioma | University of Southern California | Withdrawn | No outcome recorded |
| Phase 1/2 | NCT00473486 Comparator | May 2007 → Aug 2008 | non-small cell lung carcinoma | University Hospital Muenster | Terminated | No outcome recorded |
| Phase 1/2 | NCT00297089 Comparator | Nov 2006 → Jan 2009 | non-small cell lung carcinoma | AbbVie | Completed | No outcome recorded |
| Phase 1/2 | NCT00408226 Background | Oct 2006 → Jun 2009 | non-small cell lung carcinoma | CASI pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 1/2 | NCT00281125 Background | Jan → Sep 2006 | neoplasm of thorax | Nevada Cancer Institute | Terminated | No outcome recorded |
| Phase 1/2 | NCT00516100 Background | Jan 2006 → Jan 2010 | non-small cell lung carcinoma | Aptium Oncology Research Network | Unknown | No outcome recorded |
| Phase 1/2 | NCT01353482 Comparator | — | malignant pleural mesothelioma | University College, London | Withdrawn | No outcome recorded |
| Phase 2232 trials | ||||||
| Phase 2 | NCT07234877 Background | Nov 2026 → Jan 2032 expected | non-small cell lung carcinoma | European Organisation for Research and Treatment of Cancer - EORTC | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07358689 Background | Jun 2026 → Jan 2028 expected | non-small cell lung carcinoma | Tianjin Medical University Cancer Institute and Hospital | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07486817 Background | Jun 2026 → Aug 2027 expected | non-small cell lung carcinoma | Boehringer Ingelheim | Recruiting | No outcome recorded |
| Phase 2 | NCT07603661 Background | Jun 2026 → Jun 2028 expected | non-small cell lung carcinoma | Sun Yat-sen University | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07420439 Comparator | May 2026 → Aug 2028 expected | interstitial lung disease, non-small cell lung carcinoma | French Cooperative Thoracic Intergroup | Not yet recruiting | No outcome recorded |
| Show all 232 trials opens the full record — a long page | ||||||
| Phase 2/323 trials | ||||||
| Phase 2/3 | NCT07365319 Background | Jun 2026 → Dec 2035 expected | non-small cell lung carcinoma | Eikon Therapeutics | Recruiting | No outcome recorded |
| Phase 2/3 | NCT07642024 Comparator | Jun 2026 → Dec 2032 expected | non-small cell lung carcinoma | Sichuan Baili Pharmaceutical Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 2/3 | NCT07662395 Background | May 2026 → Jan 2030 expected | — | Sinocelltech Ltd. | Recruiting | No outcome recorded |
| Phase 2/3 | NCT07063745 Comparator | Jan 2026 → Aug 2031 expected | — | Bristol-Myers Squibb | Recruiting | No outcome recorded |
| Phase 2/3 | NCT07100080 Comparator | Nov 2025 → Dec 2028 expected | non-small cell lung carcinoma | Bristol-Myers Squibb | Recruiting | No outcome recorded |
| Phase 2/3 | NCT07005102 Background | Aug 2025 → Dec 2031 expected | non-small cell lung carcinoma | AbbVie | Recruiting | No outcome recorded |
| Phase 2/3 | NCT07076693 Background | Jun 2025 → May 2028 expected | non-small cell lung carcinoma | Shanghai Chest Hospital | Active not recruiting | No outcome recorded |
| Phase 2/3 | NCT06712316 Background | Jan 2025 → Feb 2029 expected | non-small cell lung carcinoma | BioNTech SE | Recruiting | No outcome recorded |
| Phase 2/3 | NCT06236438 Background | Apr 2024 → Oct 2031 expected | non-small cell lung carcinoma | AbbVie | Recruiting | No outcome recorded |
| Phase 2/3 | NCT06335355 Background | Mar 2024 → Oct 2028 expected | non-small cell lung carcinoma | Shanghai Shengdi Pharmaceutical Co., Ltd | Not yet recruiting | No outcome recorded |
| Phase 2/3 | NCT05800015 Background | Aug 2023 → Jan 2030 expected | non-small cell lung carcinoma | Regeneron Pharmaceuticals | Active not recruiting | No outcome recorded |
| Phase 2/3 | NCT05096663 Comparator | Mar 2022 → Jun 2027 expected | non-small cell lung carcinoma | SWOG Cancer Research Network | Active not recruiting | No outcome recorded |
| Phase 2/3 | NCT04702009 Background | Jan 2021 → Oct 2025 | non-small cell lung carcinoma | Shanghai Pulmonary Hospital, Shanghai, China | Completed | No outcome recorded |
| Phase 2/3 | NCT04619797 Background | Dec 2020 → Apr 2024 | non-small cell lung carcinoma | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 2/3 | NCT04750083 Background | Sep 2020 → Sep 2022 | non-small cell lung carcinoma | Taizhou Hanzhong Biomedical Co., Ltd. | Unknown | No outcome recorded |
| Phase 2/3 | NCT02709512 Background | Aug 2017 → Aug 2022 | mesothelioma | Polaris Group | Completed | No outcome recorded |
| Phase 2/3 | NCT02784171 Comparator | Nov 2016 → Oct 2024 | mesothelioma | Canadian Cancer Trials Group | Completed | No outcome recorded |
| Phase 2/3 | NCT02777788 Comparator | Sep 2014 → Dec 2019 | cancer | Shanghai University of Traditional Chinese Medicine | Unknown | No outcome recorded |
| Phase 2/3 | NCT01907100 Background | Sep 2013 → Mar 2018 | mesothelioma | Boehringer Ingelheim | Terminated | No outcome recorded |
| Phase 2/3 | NCT01774578 Background | Feb 2013 → May 2016 | non-small cell lung carcinoma | NewLink Genetics Corporation | Terminated | No outcome recorded |
| Phase 2/3 | NCT01579630 Background | Mar 2011 → Jun 2013 | non-small cell lung carcinoma | Taipei Veterans General Hospital, Taiwan | Unknown | No outcome recorded |
| Phase 2/3 | NCT01769066 Background | Dec 2009 → Feb 2014 | non-small cell lung carcinoma | Fudan University | Completed | No outcome recorded |
| Phase 2/3 | NCT00651456 Comparator | Feb 2008 → Jan 2015 | mesothelioma | French Cooperative Thoracic Intergroup | Completed | No outcome recorded |
| Phase 3186 trials | ||||||
| Phase 3 | NCT07680790 Comparator | Sep 2026 → Dec 2031 expected | non-small cell lung carcinoma | Bristol-Myers Squibb | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07672223 Comparator | Jun 2026 → Sep 2029 expected | non-small cell lung carcinoma | CSPC Megalith Biopharmaceutical Co.,Ltd. | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07633873 Comparator | Jun 2026 → Sep 2027 expected | non-small cell lung carcinoma | CSPC Megalith Biopharmaceutical Co.,Ltd. | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07376382 Comparator | Jun → Dec 2026 expected | non-small cell lung carcinoma | CSPC Megalith Biopharmaceutical Co.,Ltd. | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07524257 Background | May 2026 → May 2029 | non-small cell lung carcinoma | ImmunityBio, Inc. | Withdrawn | No outcome recorded |
| Show all 186 trials opens the full record — a long page | ||||||
| Phase 48 trials | ||||||
| Phase 4 | NCT06824792 Background | Mar 2025 → Feb 2028 expected | cancer | NING LI | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT06276933 Background | Feb 2024 → Nov 2025 overdue | lung cancer | Tongji University | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT05689671 Comparator | Dec 2023 → Mar 2026 overdue | non-small cell lung carcinoma | Nikolaj Frost MD | Active not recruiting | No outcome recorded |
| Phase 4 | NCT05583188 Background | Feb 2023 → Feb 2024 | non-small cell lung carcinoma | Galvanize Therapeutics, Inc. | Terminated | No outcome recorded |
| Phase 4 | NCT03986528 Comparator | Aug 2019 → Mar 2022 | non-small cell lung carcinoma | Jie Li | Unknown | No outcome recorded |
| Phase 4 | NCT02804646 Background | Jun 2016 → Dec 2017 | lung adenocarcinoma | Anhui Provincial Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT02195453 Background | Aug 2014 → Sep 2016 | non-small cell lung carcinoma | Shandong Cancer Hospital and Institute | Unknown | No outcome recorded |
| Phase 4 | NCT01442909 Comparator | Mar 2008 → Sep 2009 | non-small cell lung carcinoma | Taipei Veterans General Hospital, Taiwan | Completed | No outcome recorded |
| Phase not applicable17 trials | ||||||
| — | NCT07337096 Background | Jan 2026 → Dec 2027 expected | non-small cell lung carcinoma | Guangzhou University of Traditional Chinese Medicine | Recruiting | No outcome recorded |
| — | NCT06484491 Background | Sep 2025 → Oct 2027 expected | non-small cell lung carcinoma | University Medical Center Groningen | Recruiting | No outcome recorded |
| — | NCT06607926 Background | Oct 2024 → Jun 2025 overdue | non-small cell lung carcinoma | Xuanwu Hospital, Beijing | Not yet recruiting | No outcome recorded |
| — | NCT06649448 Background | Oct 2024 → Dec 2025 overdue | neutropenia | Shandong Cancer Hospital and Institute | Not yet recruiting | No outcome recorded |
| — | NCT05834413 Background | May 2023 → Jun 2027 expected | lung cancer | Shanghai University of Traditional Chinese Medicine | Recruiting | No outcome recorded |
| — | NCT05378334 Background | Jun 2022 → Sep 2027 expected | non-small cell lung carcinoma | Guangzhou University of Traditional Chinese Medicine | Recruiting | No outcome recorded |
| — | NCT04950400 Background | Jul 2021 → Dec 2023 | non-small cell lung carcinoma | Beijing Chest Hospital | Unknown | No outcome recorded |
| — | NCT07053215 Comparator | Dec 2020 → Dec 2024 | non-small cell lung carcinoma | The First Hospital of Hebei Medical University | Completed | No outcome recorded |
| — | NCT04552613 Comparator | Nov 2020 → Sep 2023 | non-small cell lung carcinoma | The Fourth Affiliated Hospital of Zhejiang University School of Medicine | Completed | No outcome recorded |
| — | NCT04482829 Background | Sep → Dec 2020 | lung adenocarcinoma | Henan University of Traditional Chinese Medicine | Unknown | No outcome recorded |
| — | NCT02951897 Comparator | Apr 2016 → Dec 2019 | lung adenocarcinoma | Third Military Medical University | Unknown | No outcome recorded |
| — | NCT02701231 Background | Nov 2015 → Dec 2020 | lung cancer | Chinese PLA General Hospital | Unknown | No outcome recorded |
| — | NCT02194738 Background | Sep 2014 → Sep 2026 expected | non-small cell lung carcinoma | National Cancer Institute (NCI) | Active not recruiting | No outcome recorded |
| — | NCT01063283 Comparator | Mar 2010 → Jun 2016 | non-small cell lung carcinoma | University of Chicago | Completed | No outcome recorded |
| — | NCT01209520 Background | Jul 2009 → Dec 2013 | non-small cell lung carcinoma | University of Miami | Completed | No outcome recorded |
| — | NCT00903292 Comparator | Mar 2009 → Apr 2010 | non-small cell lung carcinoma | National Cheng-Kung University Hospital | Unknown | No outcome recorded |
| — | NCT01004601 Comparator | Mar 2005 → Oct 2008 | non-small cell lung carcinoma | Chang Gung Memorial Hospital | Completed | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2021-06-25 | Novartis Pharmaceuticals | Sandoz announces EU launch of ready-to-dilute generic Pemetrexed to treat most prevalent form of lung cancer novartis.com ↗ |
Evidence & citations 43 cited values
Every value below carries the sentence it was read from. 1,321 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Pemetrexed | “Pemetrexed (500mg/m2) plus Carboplatin (AUC5)or Pemetrexed (500mg/m2) plus Cisplatin (75mg/m2) on Day 1 of 21day cycles (every 3 weeks) for 4\~6 cycles, followed by pemetrexed...” NCT04951648 ↗1269“Squamous cell carcinoma: Paclitaxel (175mg/m²) or Docetaxel (60-75 mg/m²) or Nab-paclitaxel (260mg/m²) plus Carboplatin (AUC=5)/Cisplatin (75 mg/m²) (to be determined by...” NCT07608159 ↗ “BACKGROUND: The efficacy and safety of axitinib, a potent and selective second-generation inhibitor of vascular endothelial growth factor receptors 1, 2, and 3 in combination...” PMID 24766732 ↗ Apr 2014 “An Open-label, Randomized Study to Evaluate the Effect of Tarceva, Compared With Alimta (Pemetrexed) or Taxotere (Docetaxel),on Survival in Patients With Advanced, Recurrent or...” NCT00556322 ↗ “intrathecal pemetrexed (administered via lumbar puncture, Ommaya reservoir, or intrathecal pump, with induction phase: 10mg twice weekly for 4 weeks, maintenance phase: 10mg...” NCT07398599 ↗ “Acceptable histology-specific PDC regimens include carboplatin plus paclitaxel or nab-paclitaxel (any histology), carboplatin/cisplatin plus pemetrexed (nonsquamous),...” NCT06865339 ↗ “platinum-based doublet chemotherapy (carboplatin [area under the curve ≤700 mg] plus pemetrexed [500 mg/m2 intravenous infusion every 3 weeks] or carboplatin [on day 1; area...” PMID 39486424 ↗ Oct 2024 “Tivantinib 360 mg twice daily in combination with other anti-cancer therapy (eg, erlotinib,sorafenib, pemetrexed, docataxel, gemcitabine, irinotecan, and/or cetuximab) at the...” NCT01178411 ↗ “IAM1363 monotherapy OR IAM1363 in combination with capecitabine + trastuzumab OR IAM1363 in combination with capecitabine + zanidatamab OR IAM1363 in combination with T-Dxd OR...” NCT06253871 ↗ “The intervention consists of furmonertinib (240 mg/d, po) combined with bevacizumab (15 mg/kg, every 3 weeks, ivgtt) and pemetrexed (50 mg) intrathecal chemotherapy /...” NCT06643000 ↗ “Non-small cell lung cancer (non-squamous cell carcinoma): pemetrexed plus carboplatin/cisplatin on Day 1 of each 21-day cycle for 4-6 cycles，pemetrexed every three weeks (Q3W)...” NCT06231680 ↗ “Non-small cell lung cancer (non-squamous cell carcinoma): pemetrexed plus carboplatin/cisplatin on Day 1 of each 21-day cycle for 4-6 cycles，pemetrexed every three weeks (Q3W)...” NCT06276933 ↗ “Neoadjuvant chemotherapy (2 cycles of cisplatin OR carboplatin accord healthcare- investigator's choice - PLUS pemetrexed fresenius AND immunotherapy (2 cycles of Opdivo PLUS 1...” NCT07121374 ↗ “A Randomized Cost-minimization Trial Comparing Pemetrexed (Alimta®) Versus Docetaxel (Taxotere®) as Second Line Treatment in Advanced Non Small Cell Lung Cancer (NSCLC): Study...” NCT00284778 ↗ “Chemotherapy: Paclitaxel 175mg/m2 D1, Carboplatin AUC=5 or DDP 75mg/m2 D1 for NSCLC; Pemetrexed 500mg/m2 D1, Carboplatin AUC=5 or DDP 75mg/m2 D1 for non-squamous NSCLC;...” NCT05940532 ↗ “with Toripalimab (240mg, d1), carboplatin (AUC=5, d1) + pemetrexed (500 mg/m2, d1) for patients with lung adenocarcinoma and carboplatin (AUC=5, d1) + albumin-bound paclitaxel...” NCT05962021 ↗ “AP regimen（Pemetrexed 500mg/m2+carboplatin AUC=5,q3w） for non-squamous cancer patientsor or TP regimen（Paclitaxel 175mg/m2+carboplatin AUC=5, or albumin paclitaxel...” NCT05378334 ↗ “Pemetrexed at a dose of 500 mg/m² plus a platinum agent (carboplatin with an area under the curve (AUC) of 5 or cisplatin at a dose of 75 mg/m²) is given by intravenous...” NCT06930794 ↗ “Induction treatment: 2 cyles of Q3W second-line plantium-based chemotherapy according to standard of care: Cisplatin or carboplatin in combination with pemetrexed, paclitaxel,...” NCT05383001 ↗ “non-Squamous NSCLC with malignant pleura effusions:Subjects receive AK112 plus Pemetrexed and Carboplatin/Cisplatin on Day 1 of every 3-week cycle (Q3W) for 4 cycles followed...” NCT06769295 ↗ “Carboplatin, cisplatin, paclitaxel, docetaxel, gemcitabine, vinorelbine, pemetrexed, or erlotinib administered on Day 1 of every 21-day cycle except gemcitabine, which was...” NCT00312728 ↗ “Platinum-based neoadjuvant chemotherapy (carboplatin at AUC 5 or 6 combined with either paclitaxel at 175 mg/m² or pemetrexed at 500 mg/m²), administered with nivolumab at 0.3...” NCT06667154 ↗ “Non-squamous NSCLC subjects will receive pemetrexed/albumin paclitaxel and platinum (cisplatin/carboplatin), and squamous NSCLC subjects will receive albumin paclitaxel and...” NCT06485557 ↗ “It consists of pemetrexed 500 mg / m2 followed 30 minutes later by cisplatin 75 mg / m2 (in the usual manner from the center to the chemotherapy) on day 1 (J1) of each cycle...” NCT02662504 ↗ “Participants in Cohort 2 will receive Osimertinib 80 mg once daily (QD) plus pemetrexed maintenance every 3 weeks (Q3W) until radiological PD as per RECIST v1.1 or other...” NCT07058519 ↗ “For non-squamous, the standard chemotherapy option of choice is carboplatin and pemetrexed. For squamous cell carcinoma, the chemotherapy used would be carboplatin and...” NCT05691829 ↗ “The other drug must contain one of the following: etoposide, vinorelbine, vinblastine, pemetrexed, taxanes (e.g., paclitaxel, docetaxel, albumin paclitaxel, paclitaxel...” NCT06424899 ↗ “investigator selected chemotherapy regimen (paclitaxel, pemetrexed or gemcitabine and other chemotherapeutic drugs which were not administered in the first-line therapy) for a...” NCT05842018 ↗ “Patients with squamous cell carcinoma received docetaxel administered in 3-week cycles, and patients with adenocarcinoma received pemetrexed, patinum and one of sintilimab or...” NCT07076693 ↗ “Enrolled eligible subjects will be started on systemic chemotherapy (pemetrexed and carboplatin or cisplatin) within 6 weeks of starting osimertinib, with the following outcome...” NCT06918782 ↗ “Patients will be treated with carboplatin or cisplatin with etoposide, paclitaxel, albumin-bound paclitaxel or pemetrexed at the discretion of the treating thoracic medical oncologist.” NCT04905316 ↗ “Concurrent chemoradiation will be with platinum-based chemotherapy (cisplatin or carboplatin, with etoposide, taxane, or pemetrexed) selected at the treating physician's discretion.” NCT04364048 ↗ “Chemotherapy (nab-paclitaxel, pemetrexed, or docetaxel) Nab-paclitaxel, also known as nanoparticle albumin-bound paclitaxel, is a chemotherapy drug used to treat certain cancers.” NCT07134413 ↗ “Chemotherapy：Vincristine/paclitaxel/docetaxel/pemetrexed/gemcitabine plus cisplatin/carboplatin：administrated for patients with NSCLC requiring post-operative adjuvant therapy.” NCT05834413 ↗ “pemetrexed 500mg/m2 IV day 1 plus cisplatin 75mg/m2 IV day 1 every 21 days OR pemetrexed 500mg/m2 IV day 1 plus carboplatin AUC 5 or 6 day 1 every 21 days investigator's choice” NCT01154140 ↗ “Patients with squamous cell carcinoma can choose paclitaxel + cisplatin/carboplatin and patients with nonsquamous cell carcinoma can choose pemetrexed + cisplatin/carboplatin.” NCT06718309 ↗ “adjuvant tislelizumab and chemotherapy (cisplatin/carboplatin + paclitaxel or cisplatin/carboplatin + pemetrexed,dependent on tumor histology and at investigator's discretion)” NCT05286957 ↗ “Intervention: Drug: Carboplatin/ Cisplatin Pemetrexed 500mg/m2, intravenous infusion, day 1;Carboplatin AUC6/ Cisplatin 75mg/m2,intravenous infusion, day 1,21 days for a cycle” NCT03992885 ↗ “Pemetrexed combined with carboplatin or cisplatin, after four cycles of combination, pemetrexed was continued as a single agent，all drugs will be administered intravenously” NCT06671379 ↗ “PCT regimens will include both carboplatin or cisplatin plus pemetrexed (for non-squamous histology) or paclitaxel (for squamous histology) in combination with cemiplimab.” NCT07274384 ↗ “Receive neoadjuvant treatment with Ensartinib (taken orally once daily) plus Pemetrexed and Carboplatin (administered intravenously every 3 weeks) for 9 weeks (3 cycles).” NCT07354061 ↗ “Pemetrexed will be administered at 500 milligram per meter square (mg/m\^2 ) IV through a 10 minute IV infusion Q3W, up to a maximum of 35 cycles (each cycle of 21 days).” NCT04581824 ↗ “Participants with non-squamous histology will receive carboplatin AUC 3 IV every 21 days and pemetrexed 375 mg/m2 IV every 21 days (collectively, induction chemotherapy).” NCT06731413 ↗ “The neoadjuvant regimen prior to radiotherapy consists of albumin-bound paclitaxel/pemetrexed, cisplatin, Bevacizumab, iparomlimab and tuvonralimab, and thymosin alpha 1.” NCT07103395 ↗ “Chemotherapy regimen: (1) for squamous cell carcinoma: cisplatin/carboplatin + paclitaxel; and (2) for non-squamous cell carcinoma: cisplatin/carboplatin + pemetrexed.” NCT06607926 ↗ “Platinum-based chemotherapy options include carboplatin, cisplatin, pemetrexed, paclitaxel, or nab-paclitaxel, administered per standard of care for up to 4 cycles.” NCT04585477 ↗ “Subjects who met the conditions of the study population were treated with Cadonilimab 10mg/kg + bevacizumab 7.5 mg/kg + carboplatin (AUC 5) + pemetrexed 500mg/m2.” NCT05812534 ↗ “Platinum based chemotherapy including cisplatin and etoposide, carboplatin and paclitaxel or cisplatin and pemetrexed (for patients with non-squamous histology).” NCT03663166 ↗ “chemotherapy, single agent including docetaxel, albumin-bound paclitaxel, vinorelbine, gemcitabine, pemetrexed, or paclitaxel, as determined by the investigator” NCT01850147 ↗ “paclitaxel or albuminotaxol or docetaxel combined with platinum, pemetrexed combined with platinum. Platinums include carboplatin, cisplatin and nedaplatin.” NCT06775275 ↗ “For non-squamous NSCLC, rh-endostatin at dose of 15mg/m2 for 5 days, 200 mg of pembrolizumab at day 1 and pemetrexed (500mg/m2,d1) are given in each cycle” NCT04094909 ↗ “Cisplatin and carboplatin are intravenously administered platinum agents that are combined with other cytotoxic chemotherapy agents such as pemetrexed.” NCT04486833 ↗ “ALIMTA (LY231514, Pemetrexed) Plus Oxaliplatin Administered Every 21 Days for First-Line Treatment of Patients With Advanced Colorectal Cancer.” NCT00034619 ↗ “A Phase 3 Trial of ALIMTA (LY231514, Pemetrexed) Plus GEMZAR Versus GEMZAR in Patients With Unresectable or Metastatic Cancer of the Pancreas.” NCT00035035 ↗ “Non-squamous carcinoma: pemetrexed 500 mg/m2, d1 + cisplatin 25 mg/m2, d1-3 or carboplatin AUC=4-6, d1,21 days for one cycle, up to 4 cycles.” NCT05472467 ↗ “Platinum-based chemotherapy (carboplatin AUC=5 + pemetrexed 500 mg/m² [adenocarcinoma] or nab-paclitaxel 260 mg/m² [squamous/other subtypes])” NCT06977074 ↗ “Cisplatin 75 mg/m² or Carboplatin AUC 5 IV every 3 weeks + Pemetrexed 500 mg/m² IV every 3 weeks) for 4 to 6 cycles, followed by Observation” NCT04334759 ↗ “Non-squamous carcinoma: pemetrexed + platinum or paclitaxel + platinum Squamous carcinoma: paclitaxel + platinum or gemcitabine + platinum” NCT05798845 ↗ “Ivonescimab (20mg/kg, Q3W) combined with chemotherapy (pemetrexed 500mg/m², gemcitabine 1000mg/m², or vinorelbine 25mg/m²) for 4 cycles.” NCT06875076 ↗ “A Phase 2 Trial of ALIMTA (Pemetrexed) Plus Gemcitabine in Locally Advanced or Metastatic Transitional Cell Carcinoma of the Urothelium” NCT00034593 ↗ “Patients with lung squamous cell carcinoma receive albumin-bound paclitaxel, and patients with lung adenocarcinoma receive pemetrexed.” NCT07561983 ↗ “Possible platinum doublet chemotherapy regimens are Cisplatin/Carboplatin in combination with Pemetrexed or Docetaxel or Gemcitabine.” NCT06902272 ↗ “pemetrexed 500 mg/m2 + carboplatin area under the plasma concentration-time curve AUC 5 or pemetrexed 500 mg/m2 + cisplatin 75 mg/m2” NCT02151981 ↗ “Patients were treated with cisplatin 75 mg/m² (first five patients 60 mg/m²) and pemetrexed 500 mg/m² every 21 days for three cycles” PMID 21415776 ↗ May 2011 “AP chemotherapy regimen was pemetrexed combined with cisplatin, and TP chemotherapy regimen was paclitaxel combined with cisplatin.” NCT05020457 ↗ “Pembrolizumab 200 mg combined with pemetrexed and platinum (investigator's choice of cisplatin or carboplatin), as indicated below:” NCT06045767 ↗ “SD and PD patients choose methotrexate + pemetrexed combined chemotherapy for 4 cycles followed by whole brain radiotherapy (WBRT)” NCT04831658 ↗ “Bevacizumab (Avastin) Plus Pemetrexed (Alimta) and Carboplatin in Previously Untreated Advanced Non-Small Cell Lung Cancer (NSCLC)” NCT00254319 ↗ “Pemetrexed (500 mg/meter square) and Carboplatin (AUC6, Calvert's formula) are administered every three weeks for three months.” NCT03472053 ↗ “Pemetrexed (500mg/m2)/Paclitaxel (260mg/m2) Carboplatin (AUC=4-5) Atezolizumab(1200mg) ivgtt, every 21 days Range from 4 cycles” NCT05295212 ↗ “subjects will be administered with PM1015 via intravenously (IV) Q2W pemetrexed until progression or accepted other treatment.” NCT05950815 ↗ “pemetrexed 500 mg/m2 plus platinum [carboplatin, area under curve (AUC) of 5, or cis-platinum 75 mg/m2] for non-squamous NSCLC” PMID 39756446 ↗ Jan 2025 “Gemcitabine will be used for squamous cell carcinomas and pemetrexed will be used for non-squamous non-small cell lung cancer.” NCT01899989 ↗ “A Trial of ALIMTA (Pemetrexed) Plus Irinotecan in Patients Who Have Been Previously Treated For Metastatic Colorectal Cancer.” NCT00034502 ↗ “Non-squamous NSCLC: pemetrexed 500 mg/m² IV over 30 min and carboplatin AUC 5 IV over 120 min or per institutional standard.” NCT07410975 ↗ “chemotherapy (Squamous cell carcinoma selective platinum + docetaxel and Adenocarcinoma selective platinum + Pemetrexed)” NCT04958993 ↗ “Non-squamous cell carcinoma: Serplulimab: 4.5mg/kg, i.v, day1 ; pemetrexed 500mg/m2, day1 ; carboplatin AUC=5, i.v, day1” NCT05882513 ↗ “Pembrolizumab (200 mg) plus chemotherapy (physicians' choice among docetaxel, pemetrexed, or vinorelbine) every 3 weeks” NCT03656094 ↗ “participants will receive oral zorifertinib plus pemetrexed administered via the Ommaya reservoir for CSF chemotherapy” NCT07551414 ↗ “furmonertinib 80mg/d for 9 weeks and cisplatin 75mg/m2 d1 iv + pemetrexed 500mg/m2 d1 iv at 21 day cycles for 3 cycles” NCT05430802 ↗ “Cisplatin 75mg/m² or carboplatin AUC 5mg/mL/min, pemetrexed 500mg/m² and pembrolizumab 200mg for non squamous NSCLC.” NCT04547504 ↗ “Pemetrexed (500 mg/m2) to be administered with cisplatin or carboplatin on Day 1 of every 3-week cycle for 3 cycles” NCT04351555 ↗ “PD-1 inhibitor plus AP regimen chemotherapy (Pemetrexed + Carboplatin or Cisplatin, every 3 weeks) for 4-6 cycles.” NCT07337096 ↗ “Aumolertinib 110 mg QD in combination with pemetrexed (500 mg/m2) plus cisplatin (75 mg/m2) or carboplatin (AUC5)” NCT04923906 ↗ “Ivonescimab (SMT112 or AK112) Plus Pemetrexed and Carboplatin via intravenous infusion (IV) Q3W, up to 4 cycles.” NCT05184712 ↗ “Subjects will receive AK112 Plus Pemetrexed and Carboplatin via intravenous infusion (IV) Q3W, up to 4 cycles.” NCT06396065 ↗ “Pemetrexed (500 mg/m2) plus carboplatin (AUC5) or cisplatin（75 mg/m²）on Day 1 of 21day cycles (every 3 weeks)” NCT07063329 ↗ “Pemetrexed will be administered prior to carboplatin as an IV infusion on Day 1 of each cycle (every 3 weeks)” NCT05241873 ↗ “Pemetrexed is a multitargeted antifolate, similar to methotrexate, but with a broader spectrum of activity.” PMID 22179954 ↗ Dec 2011 “carboplatin AUC 5, plus pemetrexed 500 mg/m² for non-squamous or paclitaxel 175 mg/m² for squamous tumors” NCT07084610 ↗ “Pemetrexed (Non-squamous NSCLC) or Nab-paclitaxel(Squamous NSCLC):Pemetrexed: 500 mg/m\^2, ivgtt, day 1.” NCT06617936 ↗ “Paclitaxel or pemetrexed are available for monotherapy for non-squamous and non-small cell lung cancer.” NCT06032052 ↗ “Pemetrexed disodium will be administered via intravenous infusion at a dose of 500 mg/m² every 3 weeks.” NCT07554859 ↗ “as well as carboplatin (area under the curve \[AUC\] of 5 on day 1) and pemetrexed (500 mg/m2 on day 1)” NCT05209256 ↗ “Pemetrexed (500 mg/m² IV on day 1) plus Carboplatin (AUC 5 mg/mL•min IV on day 1) of each 3-week cycle.” NCT07053215 ↗ “Chemotherapy options include: carboplatin or cisplatin along with pemetrexed, paclitaxel or gemcitabine” NCT06800339 ↗ “Pemetrexed and cisplatin are the standard chemotherapy regimen to treat malignant pleural mesothelioma.” NCT01675765 ↗ “FDA approved drugs for the study population: Bevacizumab, Docetaxel, Erlotinib, Gemcitabine, Pemetrexed” NCT02045446 ↗ “Intrathecal chemotherapy with 40mg of pemetrexed and 2mg of dexamethasone, every 3 weeks as one cycle.” NCT07304739 ↗ “pemetrexed (500 mg/m2 for non-squamous carcinoma) or nab-paclitaxel (260 mg/m2 for squamous carcinoma)” NCT06709859 ↗ “pemetrexed + cisplatin, pemetrexed + carboplatin, or paclitaxel + carboplatin, depending on histology.” NCT03322566 ↗ “Pemetrexed (500mg/m²day 1 intravenously) plus carboplatin (AUC=5,day 1,intravenously) every 21 days.” NCT03267654 ↗ “Pemetrexed (Alimta) when administered concurrently with carboplatin and thoracic radiation therapy.” NCT00330044 ↗ “MTD of bortezomib administered Days 1 and 8 plus 500 mg/m2 pemetrexed on day 1, every three weeks.” NCT00516100 ↗ “Platinum-based chemotherapy: pemetrexed combined with carboplatin, D1-2, Q21, a total of 4 cycles.” NCT05675033 ↗ “or pemetrexed 500 mg/m2 plus cisplatin 75 mg/m2 on day 1 every 3 weeks for non-squamous carcinoma” PMID 34280355 ↗ Jul 2021 “Pemetrexed: 500mg/m2, administered intravenously every three weeks on the first day of each cycle” NCT05448781 ↗ “Participants will receive FMT combined with tislelizumab + pemetrexed + platinum-based treatment” NCT06403111 ↗ “Drug: Pemetrexed, 500mg/m2 D1 IV Q3W or Albumin paclitaxel 260mg/m2，D1 or 130mg/m2，D1,8 IV Q3W” NCT06714708 ↗ “First-line chemotherapy: pemetrexed/cisplatin for 4 cycles. Maintenance treatment: pemetrexed.” NCT01719536 ↗ “the specific PC chemotherapy regimen is as follows: pemetrexed 500 mg/m², intravenous infusion” NCT07271602 ↗ “anti-PD-1 monoclonal antibody Toripalimab injection combined with Pemetrexed and carboplatin” NCT03513666 ↗ “pemetrexed was given 500 mg/m\^2 i.v. on day 1 for nonsquamous, every 21 days for 2 cycles.” NCT04181372 ↗ “Paclitaxel plus platinum-based chemotherapy or pemetrexed plus platinum-based chemotherapy.” NCT07052669 ↗ “Pemetrexed Cisplatin Schedule : CDDP 75 mg/m² D1, pemetrexed 500 mg/m² D1 D1=D21, 4 cycles” NCT00775385 ↗ “(carboplatin or cisplatin based on investigator's choice) + pemetrexed intravenously (IV)” NCT05607550 ↗ “Serplulimab+Paclitaxel+Cisplatin/Carboplatin Serplulimab+Pemetrexed+Cisplatin/Carboplatin” NCT05775796 ↗ “Pemetrexed/Platinum (Carboplatin orCisplatin+Pemetrexed) administered intravenously (IV).” NCT02327078 ↗ “then receive Sintilimab + Carboplatin/Cisplatin + Pemetrexed every 3 weeks for 3 cycles.” NCT07038460 ↗ “Pemetrexed is designed to block enzymes in the body that are important for tumor growth.” NCT00508144 ↗ “4. (Non-squamous histology) Pemetrexed consolidation 500mg/m2 every 21 days for 4 cycles” NCT01336543 ↗ “pemetrexed 500 mg/m2 should be administered as intravenous (IV) infusion over 10 minutes” NCT02649829 ↗ “Carboplatin AUC 5-6 mg/ml/min or cisplatin 75 mg/m2 (d4) +pemetrexed 500 mg/m2 (d4) Q3W” NCT05574998 ↗ “pemetrexed + carbo/cis or paclitaxel + carbo or docetaxel + carbo/cis for non squamous” NCT06003075 ↗ “Gemcitabine 1000mg/m² or Pemetrexed 500mg/m² IV drip on D1 and D8,21 days for a cycle.” NCT02195453 ↗ “Pemetrexed 500mg/m2 intrvenously q 3 weeks till progression or unacceptable toxicity.” NCT01593293 ↗ “Pemetrexed 500 mg/m², D1 (D1=D22, 4 cycles) Cisplatin 75 mg/m², D1 (D1=D22, 4 cycles)” NCT01102231 ↗ “Intravenous, pemetrexed 500 mg/m\^2 plus either cisplatin (75 mg/m\^2) or carboplatin” NCT05338970 ↗ “pemetrexed 500mg per kg q3w/gemcitabine 1000mg per kg q3w and carboplatin AUC=5 q3w” NCT03002844 ↗ “Pemetrexed or nab-paclitaxel +carboplatin, intravenous, every 3 weeks for 2 cycles” NCT06198907 ↗ “First-line: Pemetrexed (500 mg/m²) + cisplatin (75 mg/m²) or carboplatin (AUC 5).” NCT07131345 ↗ “If insensitive, the patient will receive six cycles of cisplatin and pemetrexed.” NCT02701231 ↗ “Chemotherapy with platinum-based double drugs(Pemetrexed,Gemcitabine,Docetaxel)” NCT03758677 ↗ “Pemetrexed Dose: 500 mg/m², administered intravenously over 10 minutes or less” NCT07177105 ↗ “Pemetrexed Dose: 500 mg/m2 every 3 weeks Route of Administration: Intravenous” NCT02709512 ↗ “ALIMTA (Pemetrexed) in Patients With Locally Advanced or Metastatic Cancer” NCT00034463 ↗ “Pemetrexed (50 mg intrathecal injection chemotherapy, once every 3 weeks).” NCT06812871 ↗ “pemetrexed 500mg/m2, intravenous infusion on the first day of each cycle” NCT04124731 ↗ “Patients received cisplatin 75mg/m2 plus pemetrexed 500 mg/m2 on day 1.” NCT01194453 ↗ “Pemetrexed-platinum combinations may be used in non- squamous carcinoma” NCT06840782 ↗ “Standard radiation and chemotherapy (cisplatin and pemetrexed) + RAD001” NCT01063478 ↗ “pemetrexed (50 mg, intrathecal chemotherapy C1d1d5, then every 3 weeks)” NCT06971406 ↗ “Pemetrexed 500mg/m\^2, IV infusion, on day-1 at every cycle of 21 days.” NCT06380348 ↗ “pemetrexed or gemcitabine in combination with cisplatin or carboplatin” NCT01951586 ↗ “non-squamous NSCLC patients will receive Pemetrexed 500mg/m2, IV, Q3W.” NCT05787613 ↗ “Cisplatin, pemetrexed, gemcitabine, carboplatin, paclitaxel, docetaxel” NCT06623656 ↗ “Drug: Pemetrexed 500 mg/m\^2 by IV infusion Q3W, given on cycle day 1” NCT04158440 ↗ “pemetrexed (500mg/m2 by IV infusion on Day 1 of each 21-28 day cycle)” NCT03986528 ↗ “May include carboplatin with gemcitabine, or paclitaxel or pemetrexed” NCT04966676 ↗ “neoadjuvant cisplatin-pemetrexed disodium (pemetrexed)-atezolizumab” NCT03228537 ↗ “The RP2D was pemetrexed 500 mg/m(2) and nab-paclitaxel 260 mg/m(2).” PMID 24013936 ↗ Sep 2013 “Intravenous (through a vein) infusions of pemetrexed and cisplatin.” NCT01445392 ↗ “Pemetrexed 500 mg/m² IV in 10 minutes followed 30 minutes later by:” NCT01296113 ↗ “Regimen 3: pemetrexed 500mg/m2 d1 + cisplatin 75 mg/m2 day1/ day1-2” NCT02883543 ↗ “Pemetrexed will be given at 500 mg/m2, D1, IV, q3w, for 3-4 cycles.” NCT05055583 ↗ “Cisplatin 75 mg/m2 days 1,22,43; Pemetrexed 500 mg/m2 days 1,22,43” NCT01416961 ↗ “Combination chemotherapy (pemetrexed, paclitaxel, or carboplatin).” NCT07111520 ↗ “Docetaxel 60-75mg/m2, 4 cycles; or pemetrexed 500mg/m2, 4 cycles.” NCT01707329 ↗ “Pemetrexed : Participants will receive 500 mg/m\^2, day 1 , Q21D” NCT05186506 ↗ “Maintenance: Pemetrexed (500mg/m²) + pembrolizumab 200mg IV q3w.” NCT07014202 ↗ “Drugs used in PC chemotherapy includes Pemetrexed and Cisplatin.” NCT04482829 ↗ “pemetrexed/paclitaxel/nab-paclitaxel plus carboplatin/cisplatin” NCT07603661 ↗ “Pemetrexed 500 mg / m2 was given on the first day of each cycle” NCT04950400 ↗ “Nab-paclitaxel or pemetrexed (per histology), intravenously Q3W” NCT07550920 ↗ “Pemetrexed will be administered at a dose of 500 mg/m\^2 IV Q3W” NCT06899126 ↗ “Carboplatin, paclitaxel, nab-paclitaxel, cisplatin, pemetrexed” NCT03774732 ↗ “P-GemOx chemotherapy (Pemetrexed + Gemcitabine + Oxaliplatin)” NCT07542912 ↗ “pemetrexed injection [500 mg/m2, administered on Day 1, Q3W]” NCT07554846 ↗ “cisplatin or carboplatin plus pemetrexed for adenocarcinoma” NCT05583188 ↗ “Chemotherapy Doublet 1: Cisplatin/carboplatin + pemetrexed.” NCT06091943 ↗ “Pemetrexed/Cisplatin or Carboplatin Pemetrexed maintenance” NCT03353675 ↗ “carboplatin AUC 5 / cisplatin 75mg/m2+ pemetrexed 500mg/m2” NCT06652048 ↗ “Pemetrexed/Cisplatin Pemetrexed/Cisplatin as chemotherapy” NCT05742607 ↗ “Cisplatin, Carboplatin, Docetaxel, Paclitaxel, Pemetrexed” NCT02064491 ↗ “or pemetrexed (500 mg/m\^2 by IV on Day 1, every 21 days)” NCT07526792 ↗ “Cisplatin/carboplatin + pemetrexed (non-squamous NSCLC)” NCT06939127 ↗ “Pemetrexed disodium for injection: , intravenous drip” NCT05416775 ↗ “Carboplatin + Pemetrexed + Bevacizumab + Atezolizumab” NCT03786692 ↗ “Non-squamus: Carboplatin AUC 5 + Pemetrexed 500mg/m2” NCT04728724 ↗ “Pemetrexed 500 mg/m\^2 during the maintenance phase.” NCT06378892 ↗ “adenocarcinoma, pemetrexed combined with carboplatin” NCT06136910 ↗ “non-squamous: carboplatin AUC5, pemetrexed 500mg/m2” NCT04379739 ↗ “Pemetrexed 500 mg/m2 on Day 1 of each 3-week cycle” NCT06475755 ↗ “Pemetrexed, cisplatin, carboplatin or gemcitibine” NCT03057106 ↗ “nonsquamous: pemetrexed + cisplatin/carboplatin” NCT04702009 ↗ “Cisplatin; Carboplatin; Pemetrexed; Paclitaxel;” NCT07672223 ↗ “Pemetrexed, 500mg/m2 D1 IV Q3W(adenocarcinoma）” NCT07138755 ↗ “paclitaxel+carboplatin or pemetrexed+cisplatin” NCT04255836 ↗ “Pemetrexed 500 mg/mq i.v. day 1 every 3 weeks” NCT02049060 ↗ “carbplatin, paclitaxel, pemetrexed, cisplatin” NCT05407675 ↗ “500mg/m2 of pemetrexed, d1 in a 21-days cycle” NCT07034391 ↗ “Pemetrexed will be 500 mg/m2 IV every 3 weeks” NCT00198133 ↗ “HS-20117 + cisplatin/carboplatin + pemetrexed” NCT06621563 ↗ “Pemetrexed 500mg/m2, intravenous drip, Day 6” NCT01564329 ↗ “Apatinib (250 mg/d) + Pemetrexed (500 mg/m2)” NCT03376737 ↗ “Pemetrexed (ALIMTA) and Gefitinib (IRESSA®)” NCT01066195 ↗ “pemetrexed (500mg/m2, intravenous drip, D1)” NCT06416930 ↗ “pemetrexed: 500 mg/m2 day 1, every 3 weeks” NCT01211275 ↗ “* pemetrexed with cisplatin or carboplatin” NCT02178397 ↗ “PD-1 antibody + pemetrexed + VEGF antibody” NCT06775743 ↗ “Pemetrexed 500mg/m2 IV (non-squamous only)” NCT03083808 ↗ “pemetrexed (for adenocarcinoma), 500mg/m2” NCT06241807 ↗ “pemetrexed ivgtt,500 mg/m2,ivgtt,d1, d22” NCT04182698 ↗ “Pemetrexed: IV, 500 mg/m2, Day1, Q3W” NCT05979818 ↗ “Pemetrexed, carboplatin or cisplatin” NCT02906150 ↗ “Pemetrexed 500 mg/m2, ivgtt，D1，Q3W” NCT07035392 ↗ “Pemetrexed 500 mg/m2 every 3 weeks” NCT05254184 ↗ “pemetrexed by intravenous infusion” NCT06692166 ↗ “Pemetrexed disodium for injection” NCT04680988 ↗ “Pemetrexed(A) 500mg/m2, IV, Day 1” NCT03706287 ↗ “Pemetrexed(A) 500mg/m2, IV, Day 1” NCT03201146 ↗ “Pemetrexed Disodium 500mg/m2，D1” NCT02621333 ↗ “pemetrexed\[500 mg/m2 IV Q3W\]” NCT07039656 ↗ “Pemetrexed (500 mg/m2 IV, D1)” NCT06969027 ↗ “Pemetrexed: 500 mg/m² D1, Q3W” NCT07358689 ↗ “Pemetrexed 500mg/m² Q3W (D1)” NCT07139041 ↗ “Pemetrexed 850 mg, IV, Day1;” NCT04897386 ↗ “Pemetrexed (500 mg/m2 IV d1)” NCT03589950 ↗ “Drug: Pemetrexed IV infusion” NCT05894889 ↗ “pemetrexed(500 mg/m², days1)” NCT07416058 ↗ “pemetrexed 500 mg/m2 IV Q3W” NCT07392658 ↗ “carboplatin and pemetrexed” NCT05315700 ↗ “pemetrexed 500mg/m2 d1 q3w” NCT01533727 ↗ “pemetrexed 500mg/m2 iv d1” NCT02103257 ↗ “pemetrexed 500 mg/m ², iv” NCT04713761 ↗ “pemetrexed 500 mg/m2 i.v.” NCT07715396 ↗ “Drug: Pemetrexed 500 mg” NCT06437977 ↗ “pemetrexed(50mg, q1-3w)” NCT06230055 ↗ “Cisplatin + pemetrexed” NCT02659059 ↗ “Antifolate: Pemetrexed” NCT03257267 ↗ “Pemetrexed, Cisplatin” NCT04322890 ↗ “pemetrexed + platinum” NCT00391586 ↗ “Pemetrexed (Alimta®)” NCT02983045 ↗ “Pemetrexed +platinum” NCT06195189 ↗ “Alimta (Pemetrexed)” NCT01172028 ↗ “Pemetrexed 500mg/m2” NCT05014464 ↗ “Pemetrexed (Alimta)” NCT01588704 ↗ “Alimta (Pemetrexed)” NCT00055432 ↗ “Pemetrexed (Alimta)” NCT01746277 ↗ “pemetrexed (500 mg” NCT07230626 ↗ “ALIMTA(Pemetrexed)” NCT00051506 ↗ “Drug: Pemetrexed” NCT00762034 ↗ “Drug: Pemetrexed” NCT00193414 ↗ “Pemetrexed” NCT01703910 ↗ “Pemetrexed” NCT03177291 ↗ |
| Known as | ALIMTA | “Pemetrexed (Alimta, Eli Lilly and Company) was administrated by intrathecal injection, first as induction therapy, twice per week for 2 weeks, followed by consolidation...” NCT06809530 ↗54“A Randomized Cost-minimization Trial Comparing Pemetrexed (Alimta®) Versus Docetaxel (Taxotere®) as Second Line Treatment in Advanced Non Small Cell Lung Cancer (NSCLC): Study...” NCT00284778 ↗ “Cisplatinum and pemetrexed (ALIMTA®) has become an effective first-line regimen for advanced and inoperable non-squamous NSCLC without somatic activating mutations of epidermal...” NCT01742767 ↗ “Pemetrexed (Alimta) is approved for use in patients with certain types of lung cancer called non-squamous non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma.” NCT06794645 ↗ “Evaluation of pemetrexed (Alimta, LY231514) as second line chemotherapy in persistent or recurrent carcinoma of the cervix: a phase II study of the Gynecologic Oncology Group.” PMID 18455781 ↗ May 2008 “A Phase I-IIa Dose-Ranging Study of Pemetrexed (Alimta) Plus Cetuximab (Erbitux) in Patients With Recurrent Non-Small Cell Lung Cancer (NSCLC): Hoosier Oncology Group LUN04-79” NCT00216203 ↗ “Pemetrexed (Alimta, Eli Lilly and Company) is administrated by intrathecal injection, plus dexamethasone, twice per week for 2 weeks, followed by once per week for 4 weeks.” NCT05289908 ↗ “The regimen of pemetrexed (Alimta, Eli Lilly and Company) is 10/15/20 mg, plus dexamethasone 5 mg, twice per week for 2 weeks, followed by once per week for 2-4 weeks.” NCT03101579 ↗ “Pemetrexed (Alimta, LY231514) (NSC #698037) in Combination With Cisplatin (NSC #119875) in the Treatment of Advanced, Persistent, or Recurrent Carcinoma of the Cervix” NCT00691301 ↗ “Phase I/II Trial of Abraxane® (ABI-007) and Alimta® (Pemetrexed) in Advanced Solid Tumors With Emphasis on Non-Small Cell Lung Cancer (NSCLC) and Breast Cancer” NCT00470548 ↗ “Pemetrexed (also known as Alimta) has been approved by the FDA for the treatment of some lung cancers and has been shown to be effective in laboratory studies.” NCT00916630 ↗ “ALIMTA (LY231514, Pemetrexed) Plus Oxaliplatin Administered Every 21 Days for First-Line Treatment of Patients With Advanced Colorectal Cancer.” NCT00034619 ↗ “A Phase 2 Trial of ALIMTA (Pemetrexed) Plus Gemcitabine in Locally Advanced or Metastatic Transitional Cell Carcinoma of the Urothelium” NCT00034593 ↗ “A Phase II Trial of Pemetrexed (ALIMTA®, LY231514, IND #40061) as Salvage Therapy for Failed Low Risk Gestational Trophoblastic Tumor” NCT00096187 ↗ “Bevacizumab (Avastin) Plus Pemetrexed (Alimta) and Carboplatin in Previously Untreated Advanced Non-Small Cell Lung Cancer (NSCLC)” NCT00254319 ↗ “A Trial of ALIMTA (Pemetrexed) Plus Irinotecan in Patients Who Have Been Previously Treated For Metastatic Colorectal Cancer.” NCT00034502 ↗ “Pemetrexed (Alimta) 500mg/\^2 administered intravenously over approximately 10-minutes on Day 1 of a 21-day cycle x 3 cycles” NCT00732303 ↗ “A Phase I Study of ALIMTA Plus Oxaliplatin Administered Every Other Week in the Treatment of Patients With Metastatic Cancer” NCT00470405 ↗ “Pemetrexed (brand name Alimta) is a chemotherapy drug manufactured and marketed by Eli Lilly and Company.” NCT03489616 ↗ “A Phase I Study of Pemetrexed (LY231514, Alimta) in Children and Adolescents With Recurrent Solid Tumors” NCT00070473 ↗ “ALIMTA (Pemetrexed) Alone or in Combination With Cisplatin for Patients With Malignant Mesothelioma.” NCT00040625 ↗ “Pemetrexed (Alimta) when administered concurrently with carboplatin and thoracic radiation therapy.” NCT00330044 ↗ “Study of Two Doses of ALIMTA (Pemetrexed) as First Line Chemotherapy for Advanced Breast Cancer” NCT00065533 ↗ “three medications given together: paclitaxel, pemetrexed (Alimta®), and bevacizumab (Avastin®).” NCT00807573 ↗ “pemetrexed (Alimta®) 500 mg/sqm i.v. on day 8 followed by gemcitabine 1,250 mg/sqm, q 3 weeks.” NCT00434135 ↗ “Combined With Pemetrexed (Alimta) and Cisplatin, a Randomized Phase II Trial.” NCT00799240 ↗ “Pemetrexed (Alimta) in combination with gemcitabine (Gemzar)” NCT00034606 ↗ “Pemetrexed (ALIMTA) and Gefitinib (IRESSA®)” NCT01066195 ↗ “pemetrexed (Alimta, LY231514, IND #40061)” NCT00087100 ↗ “pemetrexed (ALIMTA LY231514, IND #40061)” NCT00087087 ↗ “Premetrexed (Alimta)” NCT00198133 ↗ “Pemetrexed (Alimta)” NCT05180799 ↗ “Pemetrexed (Alimta)” NCT07001618 ↗ “Pemetrexed (Alimta)” NCT06908993 ↗ “Pemetrexed (Alimta)” NCT06762080 ↗ “pemetrexed (Alimta)” NCT00903292 ↗ “Pemetrexed (Alimta)” NCT06809517 ↗ “Pemetrexed (Alimta)” NCT00440414 ↗ “Alimta (Pemetrexed)” NCT00055432 ↗ “Pemetrexed (Alimta)” NCT00891579 ↗ “ALIMTA(Pemetrexed)” NCT00051506 ↗ |
| Known as | Alimta (brand name for Pemetrexed) | “Alimta (brand name for Pemetrexed)” NCT04107103 ↗ |
| Known as | Alimta (pemetrexed) | “Alimta (pemetrexed)” NCT00516100 ↗ |
| Known as | Alimta [Registered Trademark] | “A Phase II Trial of Pemetrexed (Alimta [Registered Trademark]) Combined With Sirolimus (Rapamycin, Rapamune [Registered Trademark]) in Subjects With Relapsed or Refractory NSCLC” NCT00923273 ↗ |
| Known as | Alimta: brand name of pemetrexed | “Alimta: brand name of pemetrexed” NCT01593293 ↗ |
| Known as | Armisarte | ChEMBL registry synonym — accepted as the source's own label CHEMBL225072 ↗ |
| Known as | Armisarte (previously pemetrexed actavis) | ChEMBL registry synonym — accepted as the source's own label CHEMBL225072 ↗ |
| Known as | Ciambra | ChEMBL registry synonym — accepted as the source's own label CHEMBL225072 ↗ |
| Known as | Duvalizumab | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04897386 ↗ |
| Known as | LY-231514 DISODIUM SALT | ChEMBL registry synonym — accepted as the source's own label CHEMBL225072 ↗ |
| Known as | LY231514 | “Evaluation of pemetrexed (Alimta, LY231514) as second line chemotherapy in persistent or recurrent carcinoma of the cervix: a phase II study of the Gynecologic Oncology Group.” PMID 18455781 ↗ May 20088“Pemetrexed (Alimta, LY231514) (NSC #698037) in Combination With Cisplatin (NSC #119875) in the Treatment of Advanced, Persistent, or Recurrent Carcinoma of the Cervix” NCT00691301 ↗ “The purpose of this study is to evaluate the effects (good and bad) of LY231514 (ALIMTA) and Carboplatin on you and your non-small cell lung cancer.” NCT00051493 ↗ “ALIMTA (LY231514, Pemetrexed) Plus Oxaliplatin Administered Every 21 Days for First-Line Treatment of Patients With Advanced Colorectal Cancer.” NCT00034619 ↗ “A Phase 3 Trial of ALIMTA (LY231514, Pemetrexed) Plus GEMZAR Versus GEMZAR in Patients With Unresectable or Metastatic Cancer of the Pancreas.” NCT00035035 ↗ “A Phase II Trial of Pemetrexed (ALIMTA®, LY231514, IND #40061) as Salvage Therapy for Failed Low Risk Gestational Trophoblastic Tumor” NCT00096187 ↗ “A Phase I Study of Pemetrexed (LY231514, Alimta) in Children and Adolescents With Recurrent Solid Tumors” NCT00070473 ↗ “pemetrexed (Alimta, LY231514, IND #40061)” NCT00087100 ↗ “pemetrexed (ALIMTA LY231514, IND #40061)” NCT00087087 ↗ |
| Known as | NSC #698037 | “Pemetrexed (Alimta, LY231514) (NSC #698037) in Combination With Cisplatin (NSC #119875) in the Treatment of Advanced, Persistent, or Recurrent Carcinoma of the Cervix” NCT00691301 ↗ |
| Known as | PEM | “PURPOSE: To establish the maximum tolerated dose (MTD) and safety profile of bi-weekly Pemetrexed (PEM) when combined with weekly cisplatin (CDDP) and standard dose external...” PMID 26810581 ↗ Jan 2016 |
| Known as | Pemebit | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02498860 ↗ |
| Known as | Pemetrexate | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00705549 ↗ |
| Known as | Pemetrexed (Alimta) | “Pemetrexed (Alimta®)” NCT02983045 ↗5“Pemetrexed (Alimta™)” NCT00604461 ↗ “Pemetrexed (Alimta)” NCT01588704 ↗ “Pemetrexed (Alimta)” NCT01746277 ↗ “pemetrexed (Alimta)” NCT01116219 ↗ “Pemetrexed/Alimta” NCT00517595 ↗ |
| Known as | Pemetrexed accord | ChEMBL registry synonym — accepted as the source's own label CHEMBL225072 ↗ |
| Known as | Pemetrexed Alvogen | “Drug: pemetrexed (Pemetrexed Alvogen) at 500 mg/m2 IV infusion on Day 1 of each 3 week cycle” NCT03562871 ↗ |
| Known as | Pemetrexed baxter | ChEMBL registry synonym — accepted as the source's own label CHEMBL225072 ↗ |
| Known as | Pemetrexed diacid monohydrate | ChEMBL registry synonym — accepted as the source's own label CHEMBL225072 ↗ |
| Known as | PEMETREXED DIPOTASSIUM | ChEMBL registry synonym — accepted as the source's own label CHEMBL225072 ↗ |
| Known as | Pemetrexed disodium | “It is not yet known whether giving gemcitabine hydrochloride or pemetrexed disodium together with carboplatin is more effective with or without celecoxib in treating non-small...” NCT01041781 ↗69“Drugs used in chemotherapy, such as pemetrexed disodium and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping...” NCT00268437 ↗ “Drugs used in chemotherapy, such as pemetrexed disodium and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them...” NCT00334594 ↗ “Carboplatin plus Pemetrexed Disodium, administrated for 2-4 cycles, three weeks for one cycyles;Carboplatin 500mg/m2 d1,Pemetrexed Disodium AUV＝5 d1,Q3W” NCT06208033 ↗ “Pemetrexed disodium in recurrent locally advanced or metastatic squamous cell carcinoma of the head and neck.” PMID 11531245 ↗ Sep 2001 “Pemetrexed disodium for injection 500 mg per square meter, intravenous drip on day 1 in each treatment cycle.” NCT04482829 ↗ “Patients receive pemetrexed disodium IV over 10 minutes and vinflunine IV over 20 minutes on day 1.” NCT00320073 ↗ “Patients receive cisplatin IV over 30 minutes and pemetrexed disodium IV over 10 minutes on day 1.” NCT00227539 ↗ “Patients receive pemetrexed disodium IV over 10 minutes and cisplatin IV over 1-4 hours on day 1.” NCT00691301 ↗ “pemetrexed disodium IV is administered over 10 minutes 90 minutes following gemcitabine on day 8.” NCT00006007 ↗ “Patients receive pemetrexed disodium IV over 10 minutes and oxaliplatin IV over 2 hours on day 1.” NCT00470405 ↗ “Pemetrexed disodium for injection: 0.2 g per vial; 500 mg/m² intravenously every 3 weeks” NCT07492342 ↗ “Patients receive pemetrexed disodium IV over 10 minutes on day 1 of radiotherapy.” NCT00573989 ↗ “Pemetrexed disodium 400 mg/m2 intravenously over 10 minutes every 14 days.” NCT00438204 ↗ “For non-squamous NSCLC: Pemetrexed disodium for injection + Carboplatin” NCT04203485 ↗ “Patients receive pemetrexed disodium IV over 10 minutes on day 1.” NCT00087113 ↗ “Pemetrexed disodium for injection: , intravenous drip” NCT05416775 ↗ “pemetrexed disodium IV over 10 minutes” NCT01116219 ↗ “Pemetrexed Disodium for Injection.” NCT06738251 ↗ “Pemetrexed Disodium for Injection.” NCT06474455 ↗ “Pemetrexed Disodium for Injection” NCT06956001 ↗ “Pemetrexed disodium for injection” NCT04680988 ↗ “Pemetrexed Disodium for Injection” NCT06970639 ↗ “pemetrexed (pemetrexed disodium)” NCT02535312 ↗ “pemetrexed (pemetrexed disodium)” NCT01784640 ↗ “pemetrexed (pemetrexed disodium)” NCT00950365 ↗ “Pemetrexed Disodium Injection” NCT05754853 ↗ “Drug: Pemetrexed Disodium” NCT04158141 ↗ “Drug: Pemetrexed Disodium” NCT02535325 ↗ “Drug: pemetrexed disodium” NCT00022646 ↗ “Drug: Pemetrexed Disodium” NCT01993810 ↗ “Drug: pemetrexed disodium” NCT01958372 ↗ “Drug: Pemetrexed Disodium” NCT04895735 ↗ “Drug: Pemetrexed Disodium” NCT03137771 ↗ “Drug: pemetrexed disodium” NCT00053209 ↗ “Drug: pemetrexed disodium” NCT00863512 ↗ “Drug: Pemetrexed Disodium” NCT03971474 ↗ “Drug: Pemetrexed Disodium” NCT04061590 ↗ “Drug: pemetrexed disodium” NCT00107419 ↗ |
| Known as | Pemetrexed disodium f Injection | “Pemetrexed disodium f Injection 500mg / m2, intravenous drip, on Day 1 in 21-day cycle.” NCT04439890 ↗ |
| Known as | Pemetrexed Disodium for Injection | “Pemetrexed Disodium for Injection: Administration and Dosage: Intravenous infusion, 500mg/m\^2; Frequency and Duration of Administration: On the first day of each cycle,and 21...” NCT06514027 ↗2“CVL006（B006 Injection）、pemetrexed（Pemetrexed Disodium for Injection）、carboplatin（Carboplatin Injection）” NCT07157956 ↗ “For non-squamous NSCLC: Pemetrexed disodium for injection + Carboplatin” NCT04203485 ↗ |
| Known as | Pemetrexed fresenius kabi | ChEMBL registry synonym — accepted as the source's own label CHEMBL225072 ↗ |
| Known as | Pemetrexed krka | ChEMBL registry synonym — accepted as the source's own label CHEMBL225072 ↗ |
| Known as | Pemetrexed lilly | ChEMBL registry synonym — accepted as the source's own label CHEMBL225072 ↗ |
| Known as | Pemetrexed medac | ChEMBL registry synonym — accepted as the source's own label CHEMBL225072 ↗ |
| Known as | PEMETREXED MONOHYDRATE | ChEMBL registry synonym — accepted as the source's own label CHEMBL225072 ↗ |
| Known as | Pemetrexed pfizer (previously known as pemetrexed hospira uk limited) | ChEMBL registry synonym — accepted as the source's own label CHEMBL225072 ↗ |
| Known as | Pemetrexed pfizer (previously pemetrexed hospira) | ChEMBL registry synonym — accepted as the source's own label CHEMBL225072 ↗ |
| Known as | Pemetrexed sandoz | ChEMBL registry synonym — accepted as the source's own label CHEMBL225072 ↗ |
| Known as | pemetrexed sodium | “Phase II: Patients undergo IMRT and receive pemetrexed sodium as in phase I.” NCT00573989 ↗ |
| Known as | Pemetrexed sodium salt | ChEMBL registry synonym — accepted as the source's own label CHEMBL225072 ↗ |
| Known as | Pemfexy | ChEMBL registry synonym — accepted as the source's own label CHEMBL225072 ↗ |
| Known as | Pemtrexed (Alimta) | “Pemtrexed (Alimta)” NCT00923637 ↗ |
| Action | Inhibit | “Pemetrexed disodium may stop the growth of tumor cells by blocking the enzymes necessary for their growth.” NCT00053209 ↗ |
| Modality | Small molecule | “Pemetrexed is a multitargeted antifolate with activity in tumor types not significantly responsive to other antifolates.” PMID 20130879 ↗ Feb 2010 |
| Route | Intravenous | “pemetrexed 500 mg/m2 (intravenous; day 8)” PMID 16303865 ↗ Nov 2005 |
| Target | DHFR | “pemetrexed disodium target genes (TS, DHFR, and GARFT)” NCT00798603 ↗ |
| Target | GART | “GAR transformylase inhibitor” CHEMBL225072 ↗ |
| Target | TYMS | “Thymidylate synthase inhibitor” CHEMBL225072 ↗ |